Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • Alzheimer’s Disease
    • ALS
    • MSA
    • Parkinson’s Disease
    • Posters & Publications
  • Clinical Trials
  • News & Media
    • Press Releases
    • Events
    • In The News
    • Videos
    • Commentary
    • Podcasts
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • NASDAQ: PMN
    • Analyst Coverage
  • SEDAR
  • SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jun 22, 2022 7:00am EDT

ProMIS Neurosciences Announces Debt Amendment and Conversion

Jun 22, 2022 7:00am EDT

ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application

Jun 22, 2022 7:00am EDT

ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares

May 17, 2022 7:00am EDT

ProMIS Neurosciences presents at the 2022 Neuro4D International Conference

May 13, 2022 7:00am EDT

ProMIS Neurosciences Announces First Quarter 2022 Results

May 13, 2022 7:00am EDT

ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved

May 03, 2022 7:00am EDT

Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend ProMIS Shareholders Vote FOR All Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

Apr 28, 2022 7:00am EDT

ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)

Apr 19, 2022 7:00am EDT

ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer

Apr 07, 2022 7:00am EDT

ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting

  • arrow_back
  • 1…
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • …24
  • arrow_forward
  • Email Alerts
  • Contacts
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy